Factors associated with cognitive impairment in patients with neuromyelitis optica spectrum disorders from Mexico [0.03%]
墨西哥神经脊髓炎谱系疾病患者的认知障碍相关因素分析
Edgar R Valdivia-Tangarife,Fabiola Gonzalez-Ponce,Alejandra Morlett-Paredes et al.
Edgar R Valdivia-Tangarife et al.
Background: Patients with neuromyelitis optica spectrum disorders (NMOSD) often experience significant functional limitation, high rates of disability, and cognitive impairment (CI). The objective of this study was evaluating the factors as...
Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis [0.03%]
一种创新的液体生物标志物组用于早期预测多发性硬化独立于复发活动进展的分析
Edoardo Dalmato Schilke,Maura Frigo,Maria Letizia Fusco et al.
Edoardo Dalmato Schilke et al.
Background: Progression independent of relapse activity (PIRA) may occur in patients with relapsing multiple sclerosis (MS) and is a major contributor to disability accumulation. ...
Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician? [0.03%]
复发或不复发：多发性硬化病活动生物标志物能支持临床医生吗？
Jeske van Pamelen,Marleen J A Koel-Simmelink,Birgit I Lissenberg et al.
Jeske van Pamelen et al.
Background: In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging. Objectives: ...
Letter to the editor regarding "Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort" [0.03%]
关于“瑞士多发性硬化队列中开始使用B细胞耗竭疗法患者的治疗依从性和临床结局”的读者来信
Joaquín Borrás-Blasco,Alejandro Valcuende-Rosique,Silvia Cornejo-Uixeda
Joaquín Borrás-Blasco
Diffusion tensor imaging in the SPRINT-MS clinical trial: Advancing trial methodology [0.03%]
SPRINT-MS临床试验中的扩散张量成像：推进试验方法学研究
Ken Sakaie,Mengke Du,Nancy Obuchowski et al.
Ken Sakaie et al.
Background: SPRINT-MS was a placebo-controlled phase 2 trial of ibudilast in secondary and primary progressive multiple sclerosis. The trial included multimodal imaging to assess brain tissue integrity. This contribution ...
Deep cervical lymph node volume decreases following B-cell depletion therapy [0.03%]
B细胞耗竭治疗后深颈淋巴结体积减少
Nikhil Lele,Sathish K Dundamadappa,Christopher C Hemond
Nikhil Lele
The deep cervical lymph nodes (dCLNs) are sites of immune presentation and B-cell maturation from the brain, and potentially involved in mechanisms of neuroinflammation. We hypothesized a reduction in dCLN volume following B-cell depletion ...
Dermatologic findings after initiation of fingolimod in patients with multiple sclerosis: A real-world experience of five-year follow-up [0.03%]
芬戈莫德治疗多发性硬化症患者的皮肤表现：五年随访的现实世界经验
Monireh Samimi,Aida Sajedi,Sepideh Paybast et al.
Monireh Samimi et al.
Background: Fingolimod was approved in 2010 for the treatment of relapsing-remitting multiple sclerosis, generally as second-line therapy. While its efficacy in reducing the relapse rate is well-recognized, the dermatolog...
Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial [0.03%]
奥瑞珠单抗治疗多发性硬化症患者前医嘱优化的随机对照试验
Naghmeh Abbasi Kasbi,Ali Rezaei,Reyhaneh Montazeri et al.
Naghmeh Abbasi Kasbi et al.
Background: Multiple sclerosis (MS), a chronic neurological disease, is typically managed with disease-modifying therapies (DMTs) to reduce relapse rates and slow disease progression. Some of these DMTs can cause infusion...
Delays in treatment initiation for patients with relapsing-remitting multiple sclerosis-A nationwide population-based study [0.03%]
复发缓解型多发性硬化症患者治疗启动延迟--一项基于全国人口的科学研究
Maiju Savolainen,Matias Viitala,Katariina Kuutti et al.
Maiju Savolainen et al.
Background: Early disease-modifying therapy (DMT) improves outcomes in patients with relapsing-remitting multiple sclerosis (pwRRMS), but reasons for delayed or absent initiation are unclear. ...
Response to therapy in a cohort of patients with late-onset multiple sclerosis [0.03%]
延发多发性硬化患者治疗效果分析：一项队列研究
Sophie Ahmad,Edith L Graham,Nicola Lancki et al.
Sophie Ahmad et al.
Background and objectives: Late-onset MS (LOMS, symptom onset after age 50) remains underrepresented in clinical trials, leading to a gap in knowledge about the efficacy of disease-modifying therapies (DMTs). This study a...